The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies

References

• Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19:474–479.
   PubMed Web of Science ®Google Scholar
• Cornejo-Juárez P, Pérez-Jiménez C, Silva-Sánchez J, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One. 2012;7:e35780.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27:200–210.
   PubMed Web of Science ®Google Scholar
• Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–850.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerging Infect Dis. 2014;20:1235–1236.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–343.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987.
   PubMed Web of Science ®Google Scholar
• Mihu CN, Rhomberg PR, Jones RN, et al. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67:266–269.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–341.
   PubMed Web of Science ®Google Scholar
• Kang C-I, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91:115–121.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kwon J-C, Choi S-M, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92:533–541.
   PubMed Web of Science ®Google Scholar
• Oliveira AL, de Souza M, Carvalho-Dias VMH, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–781.
   PubMed Web of Science ®Google Scholar
• Ha YE, Kang C-I, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42:403–409.
   PubMed Web of Science ®Google Scholar
• Metan G, Demiraslan H, Kaynar LG, et al. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis. 2013;17:143–149.
   PubMed Web of Science ®Google Scholar
• Yemişen M, Balkan İİ, Salihoğlu A, et al. The changing epidemiology of blood stream infections and resistance in haematopoietic stem cell transplantation recipients. Turk J Haematol. 2015. [Epub ahead of print]. doi: 10.4274/tjh.2014.0378.
   Google Scholar
• Hyle EP, Lipworth AD, Zaoutis TE, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005;165:1375–1380.
   PubMedGoogle Scholar
• Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother. 2012;56:1870–1876.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2013;58:833–838.
   PubMed Web of Science ®Google Scholar
• Lee N-Y, Lee C-C, Huang W-H, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56:488–495.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
   PubMed Web of Science ®Google Scholar
• Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001;45:3548–3554.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161–182.
   PubMed Web of Science ®Google Scholar
• Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585–590.
   PubMed Web of Science ®Google Scholar
• Choi S-H, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008;52:995–1000.
   PubMed Web of Science ®Google Scholar
• Kara Ö, Zarakolu P, Aşçioğlu S, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47:686–693.
   PubMed Web of Science ®Google Scholar
• Kang C-I, Pai H, Kim S-H, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother. 2004;54:1130–1133.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Girdwood SCT, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:781–788.
   PubMed Web of Science ®Google Scholar
• Lee N-Y, Lee C-C, Li C-W, et al. Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates. Antimicrob Agents Chemother. 2015;59:7558–7563.
   PubMed Web of Science ®Google Scholar
• Marcos M, Iñurrieta A, Soriano A, et al. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother. 2008;62:397–403.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296–306.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–1283.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50:282–288.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infect Dis. 2011;17:1791–1798.
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873–5884.
   PubMed Web of Science ®Google Scholar
• Hussein K, Sprecher H, Mashiach T, et al. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–671.
   PubMed Web of Science ®Google Scholar
• Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83:307–313.
   PubMed Web of Science ®Google Scholar
• Gasink LB, Edelstein PH, Lautenbach E, et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–1185.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Cohen N, Ma KC, et al. Prevalence, risk factors, and outcomes of bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies [abstract #434]. Poster presented at: IDWeek; 2014 Oct 9; Philadelphia, PA.
   Google Scholar
• Freire MP, Pierrotti LC, Filho HHC, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34:277–286.
   PubMed Web of Science ®Google Scholar
• Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014;26:51–56.
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58:2740–2746.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Rodriguez V. Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer. 1973;9:435–441.
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23–E30.
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–1971.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621–1629.
   PubMed Web of Science ®Google Scholar
• Marquez P, Terashita D, Dassey D, et al. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol. 2013;34:144–150.
   PubMed Web of Science ®Google Scholar
• Sanchez GV, Master RN, Clark RB, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998–2010. Emerging Infect Dis. 2013;19:133–136.
   PubMed Web of Science ®Google Scholar
• Sweileh WM. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fundam Clin Pharmacol. 2009;23:515–520.
   PubMed Web of Science ®Google Scholar
• Van Maarseveen E, van Buul-Gast M-C, Abdoellakhan R, et al. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother. 2014;69:2581–2583.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–2113.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study–authors’ response. J Antimicrob Chemother. 2015;70:2922.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mills JC, Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59:3509–3517.
   PubMed Web of Science ®Google Scholar
• Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266–271.
   PubMed Web of Science ®Google Scholar
• Schimpff SC, Greene WH, Young VM, et al. Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer. 1973;9:449–455.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30:S51–S59.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634–640.
   PubMed Web of Science ®Google Scholar
• Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501–509.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382.
   PubMed Web of Science ®Google Scholar
• Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994;38:547–557.
   PubMed Web of Science ®Google Scholar
• Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442–3447.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Bonomo RA, Bahniuk N, et al. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:231–242.
   PubMed Web of Science ®Google Scholar
• Louie A, Grasso C, Bahniuk N, et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother. 2010;54:2646–2654.
   PubMed Web of Science ®Google Scholar
• Louie A, Bied A, Fregeau C, et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother. 2010;54:2638–2645.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363.
   PubMed Web of Science ®Google Scholar
• Bauer KA, West JE, O’Brien JM, et al. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57:2907–2912.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–6310.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46:53–59.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582.
   PubMed Web of Science ®Google Scholar
• Seo SK, Xiao K, Huang Y-T, et al. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study. J Infect. 2014;69:341–351.
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49–S56.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59:S367–S373.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271–1281.
   PubMed Web of Science ®Google Scholar
• Turkoglu M, Mirza E, Tunçcan OG, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011;26:460–467.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim SI, Hong K-W, et al. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci. 2012;27:471–475.
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Pruetpongpun N, Tiamsak P, et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents. 2014;43:378–382.
   PubMed Web of Science ®Google Scholar
• Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59: S374–S380.
   PubMed Web of Science ®Google Scholar
• Chang Y-T, Lin C-Y, Chen Y-H, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.
   PubMed Web of Science ®Google Scholar
• Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25:2–41.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Fan X, et al. Prevalence of resistant Gram-Negative Bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study. Medicine (Baltimore). 2015;94:e1931.
   PubMed Web of Science ®Google Scholar
• Cairo J, Hachem R, Rangaraj G, et al. Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011;17:1711–1716.
   PubMed Web of Science ®Google Scholar
• Lai C-H, Chi C-Y, Chen H-P, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004;37:350–358.
   PubMedGoogle Scholar
• Metan G, Hayran M, Hascelik G, et al. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J Infect Dis. 2006;38:527–531.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol. 2003;24:269–274.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Sevim M, Pala Ç, et al. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients. Int J Hematol. 2013;97:414–420.
   PubMed Web of Science ®Google Scholar
• Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31:705–711.
   PubMed Web of Science ®Google Scholar
• Cho S-Y, Lee D-G, Choi S-M, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15:69.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735–2737.
   PubMed Web of Science ®Google Scholar
• Wang YL, Scipione MR, Dubrovskaya Y, et al. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58:176–182.
   PubMed Web of Science ®Google Scholar
• Cho SY, Kang C-I, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58:581–583.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY antimicrobial surveillance program, 2009-2012. Int J Antimicrob Agents. 2014;43:328–334.
   PubMed Web of Science ®Google Scholar
• Hand E, Davis H, Kim T, et al. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 2016;71:1071–1075.
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014;15:e606–e619.
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Worth LJ, Thursky KA, et al. The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol. 2015;79:195–207.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.
   PubMed Web of Science ®Google Scholar
• Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2009;30:447–452.
   PubMed Web of Science ®Google Scholar
• Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 2010;31:620–626.
   PubMed Web of Science ®Google Scholar
• Fukuta Y, Muder RR, Agha ME, et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control. 2013;41:1249–1252.
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Kern WV, Livermore DM. ECIL-4, A Joint Venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825.
   PubMed Web of Science ®Google Scholar
• Oren I, Sprecher H, Finkelstein R, et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am J Infect Control. 2013;41:1167–1172.
   PubMed Web of Science ®Google Scholar
• Halaby T, Al Naiemi N, Kluytmans J, et al. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother. 2013;57:3224–3229.
   PubMed Web of Science ®Google Scholar
• Lübbert C, Faucheux S, Becker-Rux D, et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents. 2013;42:565–570.
   PubMed Web of Science ®Google Scholar
• Strenger V, Gschliesser T, Grisold A, et al. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns. Int J Antimicrob Agents. 2011;37:67–69.
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Benyamini N, Sprecher H, et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 2011;46:1226–1230.
   PubMed Web of Science ®Google Scholar
• Vehreschild MJGT, Hamprecht A, Peterson L, et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014;69:3387–3392.
   PubMed Web of Science ®Google Scholar
• Cornejo-Juárez P, Suárez-Cuenca JA, Volkow-Fernández P, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer. 2016;24:253–259.
   PubMed Web of Science ®Google Scholar
• Nesher L, Rolston KVI, Shah DP, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17:33–38.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Teng CB, Cunningham SA, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61:1071–1080.
   PubMed Web of Science ®Google Scholar